{"Clinical Trial ID": "NCT00463788", "Intervention": ["INTERVENTION 1:", "- Cisplatin and Cetuximab", "Cisplatin 75 milligrams per square metre (mg/m^2) intravenous infusion (IV) administered on day 1 up to every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by an intravenous infusion of 250 mg/m^2 per week.", "INTERVENTION 2:", "- Cisplatin", "A cisplatin infusion 75 mg/m^2 IV is given on day 1 up to 3 weeks with a maximum of 6 cycles until the first occurrence of a PD, unacceptable toxicity or withdrawal of consent."], "Eligibility": ["Incorporation criteria:", "A histologically confirmed diagnosis of metastatic breast cancer (Stage IV)", "Estrogen receptor [ER] negative, PgR negative and HER2 less than 3+ immunohistochemical expression (IHC)", "No more than one previous chemotherapy received for the treatment of this metastatic breast cancer", "Not more than one previous diet of anthracycline and/or taxane (whether adjuvant or metastatic)", "Other inclusion criteria defined by the protocol may apply.", "- Exclusion criteria:", "Previous platinum agent", "Previous Mitomycin", "\u2022 Known history of brain metastases", "Other exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Best overall response (BOR)", "Percentage of participants with the best overall assessment (objective) based on the response of the confirmed complete response (RC) or confirmed partial response (PR) according to the solid tumour response assessment criteria (RCIST).", "Timeline: Evaluations were conducted every 6 weeks until progress was reported between the day of the first randomized participant, June 20, 2007, until the deadline, July 31, 2009", "Results 1:", "Title of the arm/group: Cisplatin and Cetuximab", "Description of the arm/group: Intravenous infusion of cisplatin at 75 milligrams per square metre (mg/m^2) administered on day 1 up to every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by a weekly intravenous infusion of 250 mg/m^2. Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or unacceptable toxicity.", "Total number of participants analysed: 115", "Type of measurement: Number", "Unit of measure: percentage of participants 20.0 (13.1-28.5)", "Results 2:", "Title of the arm/group: Cisplatin", "Description of the arm/group: Cisplatin infusion 75 mg/m^2 IV administered on day 1 up to every 3 weeks with a maximum of 6 cycles until the first onset of PD, unacceptable toxicity or withdrawal of consent.", "Total number of participants analysed: 58", "Type of measurement: Number", "Unit of measure: percentage of participants 10.3 (3.9 to 21.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 41/114 (35.96 per cent)", "Anemia * 3/114 (2.63 %)", "Leukopenia * 1/114 (0.88%)", "Thrombocytopenia * 1/114 (0.88%)", "Tachycardia * 0/114 (0.00 %)", "Abdominal distension * 1/114 (0.88%)", "Abdominal pain * 1/114 (0.88%)", "Diarrhoea * 3/114 (2.63 %)", "Intestinal obstruction * 0/114 (0.00 %)", "Melaena * 1/114 (0.88%)", "Nausea * 2/114 (1.75%)", "Vomiting * 1/114 (0.88%)", "Asthenia * 2/114 (1.75 %)", "Adverse Events 2:", "Total: 13/57 (22.81 per cent)", "Anemia * 0/57 (0.00 %)", "Leucopenia * 0/57 (0.00 %)", "Thrombocytopenia * 0/57 (0.00 %)", "Tachycardia * 1/57 (1.75%)", "Abdominal distension * 0/57 (0.00 %)", "Abdominal pain * 0/57 (0.00 %)", "Diarrhoea * 0/57 (0.00 %)", "Intestinal obstruction * 1/57 (1.75%)", "Melaena * 0/57 (0.00 %)", "Nausea * 0/57 (0.00 %)", "Vomiting * 1/57 (1.75%)", "Asthenia * 0/57 (0.00 %)"]}